BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Liaw YF. Clinical utility of HBV surface antigen quantification in HBV e antigen-negative chronic HBV infection. Nat Rev Gastroenterol Hepatol. 2019;16:631-641. [PMID: 31477873 DOI: 10.1038/s41575-019-0197-8] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Maggi E, Azzarone BG, Canonica GW, Moretta L. What we know and still ignore on COVID-19 immune pathogenesis and a proposal based on the experience of allergic disorders. Allergy 2022;77:1114-28. [PMID: 34582050 DOI: 10.1111/all.15112] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Akbar SMF, Al Mahtab M, Cesar Aguilar J, Uddin MH, Khan MSI, Yoshida O, Penton E, Gerardo GN, Hiasa Y. Exploring evidence-based innovative therapy for the treatment of chronic HBV infection: experimental and clinical. Exploration of Medicine. [DOI: 10.37349/emed.2021.00058] [Reference Citation Analysis]
3 Lee KC, Cheng JS, Chang ML, Chien RN, Liaw YF. Comparable outcomes of decompensated chronic hepatitis B patients treated with entecavir or tenofovir: an 8-year cohort study. Hepatol Int 2022. [PMID: 35699864 DOI: 10.1007/s12072-022-10357-0] [Reference Citation Analysis]
4 Bong JH, Kim HR, Jung J, Park JH, Sung JS, Lee CK, Choi KH, Shin SS, Kang MJ, Kim HO, Lee DY, Pyun JC. Switching-peptides for one-step immunoassay and its application to the diagnosis of human hepatitis B. Biosens Bioelectron 2021;178:112996. [PMID: 33524706 DOI: 10.1016/j.bios.2021.112996] [Reference Citation Analysis]
5 Medas R, Liberal R, Macedo G. Discontinuation of antiviral therapy in chronic hepatitis B patients. World J Clin Cases 2021; 9(24): 6979-6986 [PMID: 34540953 DOI: 10.12998/wjcc.v9.i24.6979] [Reference Citation Analysis]
6 Li C, Zhang Y, Wan Y, Wang J, Lin J, Li Z, Huang P. STING-activating drug delivery systems: Design strategies and biomedical applications. Chinese Chemical Letters 2021;32:1615-25. [DOI: 10.1016/j.cclet.2021.01.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
7 Lim JH, Yu JH, Suh YJ, Lee JW, Jin YJ. Association between HBs Ag quantification and the risk of hepatocellular carcinoma in patients treated with tenofovir disoproxil fumarate or entecavir. Medicine (Baltimore) 2021;100:e27417. [PMID: 34596169 DOI: 10.1097/MD.0000000000027417] [Reference Citation Analysis]
8 Ou G, He L, Wang L, Song J, Lai X, Tian X, Wang L, Zhang K, Zhang X, Deng J, Zhuang H, Xiang K, Li T. The Genotype (A to H) Dependent N-terminal Sequence of HBV Large Surface Protein Affects Viral Replication, Secretion and Infectivity. Front Microbiol 2021;12:687785. [PMID: 34305848 DOI: 10.3389/fmicb.2021.687785] [Reference Citation Analysis]
9 Jeng WJ, Liu YC, Peng CW, Chien RN, Liaw YF. Highly significant differences in HBsAg kinetics among patients with two types of hepatitis B flare, with and without retreatment. J Antimicrob Chemother 2021:dkab360. [PMID: 34618028 DOI: 10.1093/jac/dkab360] [Reference Citation Analysis]
10 Tout I, Lampertico P, Berg T, Asselah T. Perspectives on stopping nucleos(t)ide analogues therapy in patients with chronic hepatitis B. Antiviral Res 2021;185:104992. [PMID: 33279523 DOI: 10.1016/j.antiviral.2020.104992] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
11 Shih C, Wu SY, Chou SF, Yuan TT. Virion Secretion of Hepatitis B Virus Naturally Occurring Core Antigen Variants. Cells 2020;10:E43. [PMID: 33396864 DOI: 10.3390/cells10010043] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
12 Pisano MB, Giadans CG, Flichman DM, Ré VE, Preciado MV, Valva P. Viral hepatitis update: Progress and perspectives . World J Gastroenterol 2021; 27(26): 4018-4044 [PMID: 34326611 DOI: 10.3748/wjg.v27.i26.4018] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Liaw YF, Chien RN. Finite nucleos(t)ide analogue therapy in hepatitis B e antigen-negative chronic hepatitis B: From an "option" to an "active recommendation". Kaohsiung J Med Sci 2022. [PMID: 35262284 DOI: 10.1002/kjm2.12518] [Reference Citation Analysis]
14 Chang ML, Liaw YF. Hepatitis B Flare in Hepatitis B e Antigen-Negative Patients: A Complicated Cascade of Innate and Adaptive Immune Responses. Int J Mol Sci 2022;23:1552. [PMID: 35163476 DOI: 10.3390/ijms23031552] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
15 Fumagalli V, Di Lucia P, Venzin V, Bono EB, Jordan R, Frey CR, Delaney W, Chisari FV, Guidotti LG, Iannacone M. Serum HBsAg clearance has minimal impact on CD8+ T cell responses in mouse models of HBV infection. J Exp Med 2020;217:e20200298. [PMID: 32761167 DOI: 10.1084/jem.20200298] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
16 Liaw YF. Finite nucleos(t)ide analog therapy in HBeAg-negative chronic hepatitis B: an emerging paradigm shift. Hepatol Int. 2019;13:665-673. [PMID: 31559604 DOI: 10.1007/s12072-019-09989-6] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 6.3] [Reference Citation Analysis]
17 Liaw YF. Hepatitis B Flare After Cessation of Nucleos(t)ide Analogue Therapy in HBeAg-Negative Chronic Hepatitis B: To Retreat or Not to Retreat. Hepatology 2021;73:843-52. [PMID: 32810321 DOI: 10.1002/hep.31525] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 13.0] [Reference Citation Analysis]
18 Lin X, Lin D, Chen Y, Lin J, Weng S, Song J, Feng S. High Throughput Blood Analysis Based on Deep Learning Algorithm and Self‐Positioning Super‐Hydrophobic SERS Platform for Non‐Invasive Multi‐Disease Screening. Adv Funct Materials 2021;31:2103382. [DOI: 10.1002/adfm.202103382] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
19 Chen X, Wang S, Tan Y, Huang J, Yang X, Li S. Nanoparticle-Based Lateral Flow Biosensors Integrated With Loop-Mediated Isothermal Amplification for the Rapid and Visual Diagnosis of Hepatitis B Virus in Clinical Application. Front Bioeng Biotechnol 2021;9:731415. [PMID: 34595159 DOI: 10.3389/fbioe.2021.731415] [Reference Citation Analysis]
20 Hu Z, Hu J, Ren F, Xu H, Tan M, Wang Q, Ren J. Nobiletin, a novel inhibitor, inhibits HBsAg production and hepatitis B virus replication. Biochem Biophys Res Commun 2020;523:802-8. [PMID: 31954513 DOI: 10.1016/j.bbrc.2019.12.099] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
21 Cheng R, Zhu F, Huang M, Zhang Q, Yan HH, Zhao XH, Luo FK, Li CM, Liu H, Liang GL, Huang CZ, Wang J. “Hepatitis virus indicator”----the simultaneous detection of hepatitis B and hepatitis C viruses based on the automatic particle enumeration. Biosensors and Bioelectronics 2022;202:114001. [DOI: 10.1016/j.bios.2022.114001] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Salpini R, Battisti A, Piermatteo L, Carioti L, Anastasiou OE, Gill US, Di Carlo D, Colagrossi L, Duca L, Bertoli A, La Rosa KY, Fabeni L, Iuvara A, Malagnino V, Cerva C, Lichtner M, Mastroianni CM, De Sanctis GM, Paoloni M, Marignani M, Pasquazzi C, Iapadre N, Parruti G, Vecchiet J, Sarmati L, Andreoni M, Angelico M, Grelli S, T Kennedy P, Verheyen J, Aquaro S, Silberstein FC, Perno CF, Svicher V. Key mutations in the C-terminus of the HBV surface glycoprotein correlate with lower HBsAg levels in vivo, hinder HBsAg secretion in vitro and reduce HBsAg structural stability in the setting of HBeAg-negative chronic HBV genotype-D infection. Emerg Microbes Infect 2020;9:928-39. [PMID: 32312174 DOI: 10.1080/22221751.2020.1757998] [Reference Citation Analysis]
23 Koutsianas C, Hadziyannis E, Thomas K, Deutsch M, Vassilopoulos D. Kinetics of quantitative hepatitis B surface antigen in patients with rheumatic disease and chronic hepatitis B receiving biologic agents. J Viral Hepat 2021. [PMID: 34496105 DOI: 10.1111/jvh.13610] [Reference Citation Analysis]
24 Chien RN, Liaw YF. Current Trend in Antiviral Therapy for Chronic Hepatitis B. Viruses 2022;14:434. [PMID: 35216027 DOI: 10.3390/v14020434] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
25 Li Y, Yin S, Chen Y, Zhang Q, Huang R, Jia B, Jie W, Yao K, Wang J, Tong X, Liu Y, Wu C. Hepatitis B virus-induced hyperactivation of B cells in chronic hepatitis B patients via TLR4. J Cell Mol Med 2020;24:6096-106. [PMID: 32391647 DOI: 10.1111/jcmm.15202] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
26 Wu ZQ, Tan L, Gan WQ, Mo ZS, Chen DB, Wang PP, Zhao QY, Xie DY, Gao ZL. The relationship between the clearance of HBsAg and the remodeling of B cell subsets in CHB patients treated with Peg-IFN-α. Ann Transl Med 2021;9:414. [PMID: 33842635 DOI: 10.21037/atm-21-409] [Reference Citation Analysis]
27 Hadziyannis E, Hadziyannis S. Current practice and contrasting views on discontinuation of nucleos(t)ide analog therapy in chronic hepatitis B. Expert Rev Gastroenterol Hepatol 2020;14:243-51. [PMID: 32162562 DOI: 10.1080/17474124.2020.1738219] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
28 Wei L, Zhao T, Zhang J, Mao Q, Gong G, Sun Y, Chen Y, Wang M, Tan D, Gong Z, Li B, Niu J, Li S, Gong H, Zou L, Zhou W, Jia Z, Tang Y, Fei L, Hu Y, Shang X, Han J, Zhang B, Wu Y. Efficacy and safety of a nanoparticle therapeutic vaccine in patients with chronic hepatitis B: A randomized clinical trial. Hepatology 2022;75:182-95. [PMID: 34396571 DOI: 10.1002/hep.32109] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
29 Terrault NA, Wahed AS, Feld JJ, Cooper SL, Ghany MG, Lisker-Melman M, Perrillo R, Sterling RK, Khalili M, Chung RT, Rosenthal P, Fontana RJ, Sarowar A, Lau DTY, Wang J, Lok AS, Janssen HLA. Incidence and prediction of HBsAg seroclearance in a prospective multi-ethnic HBeAg-negative chronic hepatitis B cohort. Hepatology 2022;75:709-23. [PMID: 34743343 DOI: 10.1002/hep.32231] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
30 de Almeida Pondé RA. Dynamic profile of the HBeAg-anti-HBe system in acute and chronic hepatitis B virus infection: A clinical-laboratory approach. Mol Biol Rep 2021;48:843-54. [PMID: 33296069 DOI: 10.1007/s11033-020-06056-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
31 Loggi E, Gitto S, Gabrielli F, Franchi E, Seferi H, Cursaro C, Andreone P. Virological Treatment Monitoring for Chronic Hepatitis B. Viruses 2022;14:1376. [DOI: 10.3390/v14071376] [Reference Citation Analysis]